Cargando…
Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase II study of FIL ONLUS
Autores principales: | Stefoni, Vittorio, Marangon, Miriam, Re, Alessandro, Lleshi, Arben, Bonfichi, Maurizio, Pinto, Antonello, Bianchetti, Nicola, Pellegrini, Cinzia, Argnani, Lisa, Zinzani, Pier Luigi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556670/ https://www.ncbi.nlm.nih.gov/pubmed/33054094 http://dx.doi.org/10.3324/haematol.2019.243170 |
Ejemplares similares
-
First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi
por: Broccoli, A., et al.
Publicado: (2019) -
Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma
por: Pellegrini, Cinzia, et al.
Publicado: (2017) -
Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
por: Chen, Runzhe, et al.
Publicado: (2015) -
Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
por: Siddiqi, Tanya, et al.
Publicado: (2014) -
Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
por: Salihoglu, A., et al.
Publicado: (2014)